Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3903880 | 0.85 | NPSR1 (0.46) | NPSR1CA2CA1CA12CA14 | |
| SCHEMBL20760744 | 0.83 | NPSR1 (0.44) | NPSR1CA2CA1CA12CA14 | |
| SCHEMBL2489155 | 0.78 | CA2 (0.43) | CA2CA1CA12CA14CA9 | |
| SCHEMBL12846705 | 0.78 | NPSR1 (0.38) | NPSR1CA2CA1CA12CA14 | |
| SCHEMBL6494972 | 0.77 | LTA4H (0.37) | CA2CA1CA12CA14 | |
| SCHEMBL10297356 | 0.76 | NPSR1 (0.36) | NPSR1CA1SIGMAR1 | |
| SCHEMBL20761989 | 0.75 | CA2 (0.50) | CA2CA1CA12CA9MAPK1 | |
| SCHEMBL3117109 | 0.74 | NPSR1 (0.44) | NPSR1CA1SIGMAR1ALDH1A1MAPK1 | |
| SCHEMBL14854988 | 0.74 | NPSR1 (0.35) | NPSR1CA1SIGMAR1 | |
| SCHEMBL6495582 | 0.73 | CA2 (0.34) | CA2CA1CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994172-B2 | [1-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methanol; kinase-dependent diseases, invasive cell growth, and metabolism | EXELIXIS, INC. (US) | 2011-08-09 | — | — | US | claimed |
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | EXELIXIS, INC. (US) | 2008-08-07 | — | — | US | claimed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| CN-109557707-B | Liquid crystal display device having a plurality of pixel electrodes | DIC株式会社 | 2022-10-21 | — | — | CN | disclosed |
| CN-110300919-B | Liquid crystal display device having a plurality of pixel electrodes | DIC株式会社 | 2022-07-01 | — | — | CN | disclosed |
| US-20200331850-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-10-22 | — | — | US | disclosed |
| US-20200331850-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-10-22 | — | — | US | disclosed |
| CN-111107903-A | Novel sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2020-05-05 | — | — | CN | disclosed |
| WO-2019034696-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20080261970-A1 | Sufonamides and Uses Thereof | ELIXIR PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
| US-20050261332-A1 | Sulfonamides and uses thereof | ELIXIR PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773058-B2 | Sulfonamide carboxamide compounds | NLRP3, NOD1, NLRP1 | NPSR1 132/4885CA2 1651/4885CA1 2065/4885 |
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | PDPK1, MTOR, RPS6KA2 | NPSR1 2860/4885CA2 2800/4885CA1 4174/4885 |
| US-20080261970-A1 | Sufonamides and Uses Thereof | CYP21A2, LPXN, OAT | NPSR1 1131/4885CA2 3198/4885CA1 2233/4885 |
| US-20200331850-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | NPSR1 142/4885CA2 1432/4885CA1 1970/4885 |
| US-20050261332-A1 | Sulfonamides and uses thereof | GLS2, STS, ABAT | NPSR1 1535/4885CA2 3211/4885CA1 2281/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | NPSR1 4167/4885CA2 735/4885CA1 1855/4885 |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | NPSR1 39/4885CA2 3515/4885CA1 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.